DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: gefitinib

Summary for Generic Name: gefitinib

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers: see list1
Therapeutic Class:Antineoplastics

Pharmacology for Ingredient: gefitinib

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

Clinical Trials for: gefitinib

Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Status: Completed Condition: Carcinoma, Non-Small-Cell Lung

Hydroxychloroquine and Gefitinib to Treat Lung Cancer
Status: Recruiting Condition: Non-small Cell Lung Cancer

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Status: Completed Condition: Myelogenous Leukemia, Acute

Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Status: Completed Condition: Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Anaplastic Oligodendroglioma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Glioblastoma; Untreated Childhood Gliomatosis Cerebri; Untreated Childhood Gliosarcoma; Untreated Childhood Oligodendroglioma

Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
Status: Completed Condition: Head and Neck Cancer

A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Status: Completed Condition: Nasopharyngeal Carcinoma

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Completed Condition: Non-Small Cell Lung Cancer

Gefitinib in Treating Children With Refractory Solid Tumors
Status: Completed Condition: Unspecified Childhood Solid Tumor, Protocol Specific

First Line Gefitinib by FDG-PET Metabolic Response
Status: Recruiting Condition: Non-small Cell Lung Cancer

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Status: Completed Condition: Skin Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca
IRESSA
gefitinib
TABLET;ORAL021399May 5, 2003DISCNNo5,770,599<disabled>YYTREATMENT OF NON-SMALL CELL LUNG CANCER
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc